Evidence map›Paper›PMID 37509311›Full record

ArticleCancers2023

Integrated Multi-Omic Analysis Reveals Immunosuppressive Phenotype Associated with Poor Outcomes in High-Grade Serous Ovarian Cancer.

Russell Keathley, Masha Kocherginsky, Ramana Davuluri, Daniela Matei

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Russell KeathleyDepartment of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Masha KocherginskyDepartment of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Ramana DavuluriDepartment of Biomedical Informatics, School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
Daniela MateiDepartment of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.ORCID 0000-0003-2169-5035

Funding

Targeting Lipid Unsaturation in Ovarian Cancer Stem CellsR01CA224275 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Ji-Xin Cheng, Daniela E Matei · 2018 to 2026
$3.6M
Developing Novel Deep-Learning Based Methods for Deciphering Non-Coding Gene Regulatory CodeR01LM013722 · NLM · STATE UNIVERSITY NEW YORK STONY BROOK · PI RAMANA V DAVULURI · 2021 to 2026
$2.0M
The Tissue Transglutaminase-Fibronectin Interaction in Ovarian Cancer MetastasisI01BX000792 · VA · RLR VA MEDICAL CENTER · PI MATEI, DANIELA E · 2011 to 2024
–
BLRD VA I01 BX000792NCI NIH HHS R01 CA224275NLM NIH HHS R01 LM013722
6 · The paper itself

Abstract

High-grade serous ovarian cancer (HGSOC) is characterized by a complex genomic landscape, with both genetic and epigenetic diversity contributing to its pathogenesis, disease course, and response to treatment. To better understand the association between genomic features and response to treatment among 370 patients with newly diagnosed HGSOC, we utilized multi-omic data and semi-biased clustering of HGSOC specimens profiled by TCGA. A Cox regression model was deployed to select model input features based on the influence on disease recurrence. Among the features most significantly correlated with recurrence were the promotor-associated probes for the NFRKB and DPT genes and the TREML1 gene. Using 1467 transcriptomic and methylomic features as input to consensus clustering, we identified four distinct tumor clusters-three of which had noteworthy differences in treatment response and time to disease recurrence. Each cluster had unique divergence in differential analyses and distinctly enriched pathways therein. Differences in predicted stromal and immune cell-type composition were also observed, with an immune-suppressive phenotype specific to one cluster, which associated with short time to disease recurrence. Our model features were additionally used as a neural network input layer to validate the previously defined clusters with high prediction accuracy (91.3%). Overall, our approach highlights an integrated data utilization workflow from tumor-derived samples, which can be used to uncover novel drivers of clinical outcomes.

Indexed as

consensus clusteringdata integrationhigh-grade serous ovarian cancer (HGSOC)multi-omic analysisneural network

Identifiers

PMID37509311
PMCPMC10377286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.